可电击与不可电击院外心脏骤停患者神经元特异性烯醇化酶的神经预后阈值不同:韩国KORHN-PRO前瞻性多中心观察研究
该研究基于韩国22所大学附属教学医院的前瞻性多中心注册(KORHN-PRO,2015年10月至2018年12月),纳入623例接受TTM且ROSC后48 h测量血清NSE的OHCA幸存者,其中245例为可电击心律。主要终点为6个月不良结局(CPC 3-5)。不可电击组NSE中位数显著高于可电击组(104.6 vs 25.9 ng/mL,P<0.001),NSE预测不良结局的AUC在不可电击组显著更高(0.92 vs 0.86)。FPR<1%的NSE阈值在不可电击组为69.3 ng/mL(敏感度42.1%),可电击组为102.7 ng/mL(敏感度76%),提示应依据初始心律采用不同阈值。
要点
- 不可电击心律OHCA幸存者TTM后48 h NSE中位数显著高于可电击者(104.6 vs 25.9 ng/mL,P<0.001)。
- NSE预测6个月不良结局(CPC 3-5)的AUC在不可电击组为0.92,显著高于可电击组的0.86。
- FPR<1%的NSE阈值:不可电击组69.3 ng/mL(敏感度42.1%),可电击组102.7 ng/mL(敏感度76%)。
- 可电击心律者达到FPR<1%所需NSE阈值更高(102.7 ng/mL),且敏感度相对较高。
- NSE预后性能及阈值因初始心律而异,提示心脏骤停后幸存者存在异质性。
适用人群与场景
- 韩国22所大学附属教学医院的前瞻性多中心注册(KORHN-PRO)中,2015年10月至2018年12月纳入的OHCA幸存者。
- 纳入接受TTM且于ROSC后48 h测量血清NSE的患者,共623例,其中245例初始心律为可电击心律。
诊断标准与关键阈值
- 主要结局为6个月不良结局,定义为大脑功能分类(CPC)3-5。
- 以FPR<1%确定NSE阈值:不可电击组69.3 ng/mL(敏感度42.1%),可电击组102.7 ng/mL(敏感度76%)。
研究设计与关键结果
- 研究类型为前瞻性多中心观察研究(KORHN-PRO注册),纳入623例接受TTM且ROSC后48 h测量NSE的OHCA幸存者,其中245例为可电击心律。
- 不可电击组NSE中位数显著高于可电击组:104.6(40.6-228.4)vs 25.9(16.7-53.4)ng/mL,P<0.001。
- NSE预测不良结局的AUC在不可电击组显著高于可电击组:0.92 vs 0.86。
- FPR<1%的NSE阈值:不可电击组69.3 ng/mL(敏感度42.1%),可电击组102.7 ng/mL(敏感度76%)。
证据类型、等级与局限
- 证据类型:前瞻性多中心观察研究(注册号KORHN-PRO,NCT02827422,2016年9月11日回顾性注册)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对TTM后OHCA幸存者解读ROSC后48 h NSE时,应按初始心律(可电击 vs 不可电击)采用不同的FPR<1%阈值。
- 不可电击心律者可采用69.3 ng/mL(敏感度42.1%)作为FPR<1%的参考阈值,可电击心律者可采用102.7 ng/mL(敏感度76%)。
- 作者认为NSE预后性能及阈值因初始心律而异,提示心脏骤停后幸存者存在异质性。
指南或共识出处
- KORHN-PRO注册研究(NCT02827422),发表于Crit Care。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Serum neuron-specific enolase (NSE) is the only recommended biomarker for multimodal prognostication in postcardiac arrest patients, but low sensitivity of absolute NSE threshold limits its utility. This study aimed to evaluate the prognostic performance of serum NSE for poor neurologic outcome in out-of-hospital cardiac arrest (OHCA) survivors based on their initial rhythm and to determine the NSE cutoff values with false positive rate (FPR) < 1% for each group.
METHODS: This study included OHCA survivors who received targeted temperature management (TTM) and had serum NSE levels measured at 48 h after return of spontaneous circulation in the Korean Hypothermia Network, a prospective multicenter registry from 22 university-affiliated teaching hospitals in South Korea between October 2015 and December 2018. The primary outcome was poor outcome at 6 month, defined as a cerebral performance category of 3-5.
RESULTS: Of 623 patients who underwent TTM with NSE measured 48 h after the return of spontaneous circulation, 245 had an initial shockable rhythm. Median NSE level was significantly higher in the non-shockable group than in the shockable group (104.6 [40.6-228.4] vs. 25.9 [16.7-53.4] ng/mL, P < 0.001). Prognostic performance of NSE assessed by area under the receiver operating characteristic curve to predict poor outcome was significantly higher in the non-shockable group than in the shockable group (0.92 vs 0.86). NSE cutoff values with an FPR < 1% in the non-shockable and shockable groups were 69.3 (sensitivity of 42.1%) and 102.7 ng/mL (sensitivity of 76%), respectively.
CONCLUSION: NSE prognostic performance and its cutoff values with FPR < 1% for predicting poor outcome in OHCA survivors who underwent TTM differed between shockable and non-shockable rhythms, suggesting postcardiac arrest survivor heterogeneity. Trial registration KORHN-PRO, NCT02827422. Registered 11 September 2016-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02827422.
参考来源
- Kim YJ, Kim YH, Youn CS, et al. Different neuroprognostication thresholds of neuron-specific enolase in shockable and non-shockable out-of-hospital cardiac arrest: a prospective multicenter observational study in Korea (the KORHN-PRO registry). Crit Care. 2023. PMID: 37559163. doi:10.1186/s13054-023-04603-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。